Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04414618
Previous Study | Return to List | Next Study

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04414618
Recruitment Status : Active, not recruiting
First Posted : June 4, 2020
Last Update Posted : January 29, 2021
Sponsor:
Information provided by (Responsible Party):
RedHill Biopharma Limited

Brief Summary:
This proof of concept study will take place in the US and other countries in approximately 15 clinical sites and will enroll about 40 hospitalized patients diagnosed with COVID-19 infection who have developed pneumonia and require supplemental oxygen. 20 patients will receive opaganib in addition to standard of care twice each day for 14 days. 20 will receive matching placebo in addition to standard of care unless the patient has been discharged from the hospital without requiring supplemental oxygen, in which case study drug will only be administered for 10 days. All participants will be followed up for 4 weeks after their last dose of study drug.

Condition or disease Intervention/treatment Phase
Coronavirus Infections Drug: Opaganib Drug: Placebo Phase 2

Detailed Description:
Opaganib, a sphingosine kinase-2 (SphK2) inhibitor, has been broadly tested in Phase I/II studies. Extensive nonclinical data indicates both anti-viral and anti-inflammatory activity via selective SphK2 inhibition which may prove beneficial for treating COVID-19 infection and resulting pneumonia. This proof of concept study will take place in the US and other countries and will enroll about 40 hospitalized patients diagnosed with COVID-19 infection who have developed pneumonia and require supplemental oxygen. Half of the patients, i.e. 20 patients, will receive opaganib in addition to standard of care for 14 days. The other 20 will receive matching placebo (capsules that do not contain the medication) in addition to standard of care. Study drug will be administered every day for 14 days, twice each day, unless the patient has been discharged from the hospital without requiring supplemental oxygen, in which case study drug will only be administered for 10 days. All participants will be followed up for 4 weeks after their last dose of study drug.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia
Actual Study Start Date : July 2, 2020
Actual Primary Completion Date : November 26, 2020
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: opaganib
Study participants will receive opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours
Drug: Opaganib
Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, in addition to standard of care (pharmacological and/or supportive).
Other Names:
  • Yeliva
  • ABC294640

Placebo Comparator: placebo
Study participants will receive placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours
Drug: Placebo
Study participants will receive placebo 2 x 250 mg capsules (500 mg) every 12 hours, in addition to standard of care (pharmacological and/or supportive).




Primary Outcome Measures :
  1. Measurement of the oxygen requirement [ Time Frame: 14 days ]
    To compare the total oxygen requirement (area under the curve) for each arm using daily supplemental oxygen flow (L/min) over 14 days


Secondary Outcome Measures :
  1. Measurement of the reduction in oxygen requirement. [ Time Frame: 14 days ]
    To comparing the time required between arms to achieve 50% reduction from baseline in supplemental oxygen based on oxygen flow in L/min

  2. Eliminating supplemental oxygen [ Time Frame: 14 days ]
    To comparing the proportion of patients in each arm no longer requiring supplemental oxygen for at least 24 hours by Day 14

  3. Elimination of fever [ Time Frame: 14 days ]
    To compare the proportion of afebrile patients in each arm at Day 14 via measurement of temperature.

  4. Time to negative swabs for SARS-CoV-2 by PCR post treatment [ Time Frame: 6 weeks ]
    To compare the time in each arm to negative swabs for SARS-CoV-2 by PCR nasopharyngeal or oropharyngeal swab for SARS-CoV-2

  5. Time to negative swabs for SARS-CoV-2 by PCR at Day 14 [ Time Frame: 14 days ]
    To comparing the time in each arm to achieve negative swabs for SARS-CoV-2 by PCR nasopharyngeal or oropharyngeal swab for SARS-CoV-2 during treatment

  6. Intubation and mechanical ventilation requirements [ Time Frame: From screening phase and every day from day 1 to day 14 of treatment ]
    To compare the percentage of patients in each arm who require intubation and mechanical ventilation by Day 14

  7. Evaluation of the time to mechanical ventilation [ Time Frame: From screening phase and every day from day 1 to day 14 of treatment ]
    To compare the time in each arm for the patient to require mechanical ventilation.

  8. Evaluation the proportion of patients, with at least one measurement of fever at baseline who are afebrile at Day 14 [ Time Frame: From screening phase and every day from day 1 to day 14 of treatment ]
    To compare the proportion of patients in each arm, with at least one measurement of fever at baseline (defined as temperature >38.0 C[100.4 F]), who are afebrile (defined as temperature <37.2C [99 F]) at Day 14

  9. Evaluation of mortality 30 days post-baseline [ Time Frame: 30 days after day 1 of treatment ]
    To compare the mortality in each arm 30 days post-baseline.


Other Outcome Measures:
  1. Safety TEAEs [ Time Frame: 6 weeks ]
    To compare the number of all treatment-emergent adverse events in each arm of all treatment-emergent adverse events (TEAEs).

  2. Safety SAEs [ Time Frame: 6 weeks ]
    To measure all serious adverse events (SAEs) in each arm.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult male or female ≥18 to ≤80 years of age
  2. Proven COVID-19 infection per RT-PCR assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) AND pneumonia defined as radiographic opacities on chest X-ray
  3. The patient requires supplemental oxygen at baseline
  4. The patient, guardian or legal representative has signed a written IRB-approved informed consent.

5) Male participants with female partners of child-bearing potential agree to one of the following methods of contraception during the treatment period and for at least 1 month after the last dose of study drug:

  • Abstinence from penile-vaginal intercourse and agree to remain abstinent.
  • Male condom, with female partner using a highly effective contraceptive method. (For further details regarding highly effective contraceptive methods please see section 9.3.)

In addition, male participants must refrain from donating sperm for the duration of the study and for 1 months after last dose of study drug.

Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration for at least 1 months after the last dose of study drug

Female participants:

A female participant is eligible to participate if she is:

  1. not pregnant
  2. not breastfeeding
  3. not a woman of child-bearing potential (WOCBP, as defined in Section 9.3)
  4. a WOCBP who agrees to use a highly effective method of contraception consistently and correctly during the treatment period and for at least 1 months after the last dose of study drug (please see further details on Section 9.3).

Exclusion Criteria:

  1. Any co-morbidity that may add risk to the treatment in the judgement of the investigator.
  2. Requiring intubation and mechanical ventilation
  3. Patient having a do not intubate or do not resuscitate order
  4. Oxygen saturation >95% on room air
  5. Any preexisting respiratory condition that requires intermittent or continuous ambulatory oxygen prior to hospitalization
  6. Patient is, in the investigator's clinical judgment, unlikely to survive >72 hours
  7. Pregnant or nursing women
  8. Unwillingness or inability to comply with procedures required in this protocol.
  9. Corrected QT (QTc) interval on electrocardiogram (ECG) >470 ms for females or >450 ms for males, calculated using Friedericia's formula (QTcF)
  10. AST (SGOT) or ALT (SGPT) > 2.5 x upper limit of normal (ULN)
  11. Bilirubin >2.0 x ULN (except where bilirubin increase is due to Gilbert's Syndrome)
  12. Serum creatinine >2.0 X ULN
  13. Absolute neutrophil count <1000 cells/mm3
  14. Platelet count <75,000/mm3
  15. Hemoglobin <8.0 g/dL
  16. Currently taking medications that are sensitive CYP3A4, CYP1A2, CYP2C9, or CYP2C19 or CYP2D6 substrates and have a narrow therapeutic index. These should be decided in discussion with the Medical Monitor on a case-by-case basis.
  17. Currently taking medications that are strong inducers or inhibitors of CYP2D6 and CYP3A4. These should be decided in discussion with the Medical Monitor on a case-by-case basis.
  18. Currently taking warfarin, apixaban, argatroban or rivaroxaban.
  19. Current drug or alcohol abuse.
  20. Currently participating in a clinical study assessing pharmacological treatments, including anti-viral studies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04414618


Locations
Layout table for location information
United States, Arizona
HonorHealth Research Institute
Scottsdale, Arizona, United States, 85258
United States, Florida
Miami Cancer Institute
Miami, Florida, United States, 33176
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
Ascension St. John Hospital
Detroit, Michigan, United States, 48236
United States, New York
Albany Medical Center
Albany, New York, United States, 12208
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
United States, Texas
Memorial Herman Southeast Hospital
Houston, Texas, United States, 77089
Memorial Hermann, Memorial City Medical Center
Houston, Texas, United States, 77204
Israel
Ziv Medical Center
Safed, Israel
Sponsors and Collaborators
RedHill Biopharma Limited
Investigators
Layout table for investigator information
Study Director: Mark L Levitt, MD, PhD RedHill Biopharma Limited
Layout table for additonal information
Responsible Party: RedHill Biopharma Limited
ClinicalTrials.gov Identifier: NCT04414618    
Other Study ID Numbers: ABC-110
First Posted: June 4, 2020    Key Record Dates
Last Update Posted: January 29, 2021
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Severe Acute Respiratory Syndrome
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases